At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 218 enrolled
Drug / intervention
EP2006 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Parallel-group, Multi-center Phase III Study Comparing the Efficacy and Safety of EP2006 and Neupogen® in Breast Cancer Patients Treated With Myelosuppressive Chemotherapy
In Brief
A Phase 3 clinical trial evaluating EP2006 and Filgrastim for Chemotherapy Associated Neutropenia and Breast Cancer. Completed, enrolled 218 participants across 26 sites in 6 countries.
Detailed Summary
The study will assess the efficacy of EP2006 compared to Filgrastim with respect to the mean duration of severe neutropenia during treatment with myelosuppressive chemotherapy in breast cancer patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChemotherapy Associated Neutropenia, Breast Cancer
CountriesCzechia, Hungary, Latvia, Russia, Slovakia, Ukraine
Collaborators--
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartDec 2011
First PostedJan 2012
Primary CompletionJun 2013
TodayJul 2026
First PostedJan 27, 2012
Enrollment StartDec 1, 2011
Primary CompletionJun 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 14.4 years ago
Interventions
EP2006drug
Eligible patients will be teated with EP2006
Filgrastimdrug
Eligible patients will be teated with Filgrastim